The patient cohort in our report had advanced‐stage gastrointestinal involvement (all stage III/IV), with the majority being non‐GCB DLBCL (66.7%), an IPI > 3 (65.4%), and TP53 mutations (61.5%). The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.